摘要
目的分析给予大肠癌患者贝伐珠单抗联合卡培他滨+奥沙利铂(XELOX)方案治疗的临床效果。方法在淮安市第五人民医院2018年11月—2019年11月治疗的大肠癌患者中遴选符合本研究标准的108例患者为对象,全部患者采取随机综合平衡法分为参考组和治疗组,各54例。治疗时,参照组采取XELOX方案治疗,治疗组采取贝伐珠单抗联合XELOX方案治疗。对比两组临床疗效、肿瘤标志物和不良反应情况。结果治疗组治疗总有效率(72.22%)明显较参照组高(53.70%),差异有统计学意义(χ^(2)=3.970,P=0.046);治疗组鳞状细胞癌相关抗原(SCC)、血清癌胚抗原(CEA)、糖类抗原125(CA125)水平显著低于参照组,差异有统计学意义(t=3.060、2.170、2.591,P<0.05);治疗组内皮素(ET)、血管性血友病因子(vWF)水平明显低于参照组,差异有统计学意义(t=3.809、3.131,P<0.05),治疗组一氧化氮(NO)水平明显高于参照组,差异有统计学意义(t=2.329,P=0.021);治疗组不良反应发生率(5.56%)显著较参照组(18.52%)低,差异有统计学意义(χ^(2)=4.285,P=0.038)。结论给予大肠癌患者贝伐珠单抗联合XELOX方案治疗的效果理想,可有效降低血清肿瘤标志物水平,且该种治疗方案基本不会造成不良反应,对改善疾病预后具有理想价值。
Objective To analyze the clinical outcomes of bevacizumab combined with oxaliplatin+capecitabine(XELOX)regimen given to patients with colorectal cancer.Methods 108 patients who met the criteria of this study were selected among the patients with colorectal cancer treated in Huai'an Fifth People's Hospital between November 2018 and November 2019.All patients were divided into a reference group and a treatment group by a randomized comprehensive balance method,and 54 cases were included in each group.In the treatment,the reference group was treated with XELOX regimen and the treatment group was treated with bevacizumab combined with XELOX regimen,the clinical efficacy,tumor markers and adverse reactions of the two groups were compared.Results The total effective rate of the treatment group(72.22%)was significantly higher than that of the reference group(53.70%),and the difference was statistically significant(χ^(2)=3.970,P=0.046).The levels of squamous cell carcinoma-related antigen(SCC),serum carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)in the treatment group were significantly lower than those in the reference group,and the differences were statistically significant(t=3.060,2.170,2.591,P<0.05);the levels of endothelin(ET),nitric oxide(NO),and von Willebrand factor(vWF)in the treatment group were significantly lower than those in the reference group,and the difference was statistically significant(t=3.809,3.131,P<0.05).The NO level in the treatment group was significantly higher than that in the reference group,and the difference was statistically significant(t=2.329,P=0.021);the incidence of adverse reactions in the treatment group(5.56%)was significantly lower than that in the reference group(18.52%),and the difference was statistically significant(χ^(2)=4.285,P=0.038).Conclusion The treatment of bevacizumab combined with XELOX regimen for patients with colorectal cancer is ideal and can effectively reduce serum tumor marker levels,and this treatment regimen basically does not cause adverse
作者
尹红英
YIN Hongying(Department of Oncology,Huai'an Fifth People's Hospital,Huai'an,Jiangsu Province,223300 China)
出处
《世界复合医学》
2022年第5期142-145,共4页
World Journal of Complex Medicine
